SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Snap, Inc. is a technology company, which engages in the provision of a visual messaging application that was created to help people communicate through short videos and images. The company was founded by Frank Reginald Brown IV, Evan Thomas Spiegel, and Robert C. Murphy in 2010 and is headquartered in Santa Monica, CA.

Snap Inc - Ordinary Shares - Class A

Snap Inc

A sharp rally and unusually heavy bullish call activity ahead of earnings are driving attention, with bulls pointing to Snaps Specs AR glasses and a proposal to sell an outside stake in the unit as potential catalysts. Others question whether the enthusiasm can last, citing ad-market concerns and the risk that options-driven momentum fades.

Okta, Inc. engages in the provision of an identity management platform for enterprises. The firm operates through the following geographical segments: United States and International. Its products include single sign-on, multi-factor authentication, access gateway, API access management, authentication, adaptive MFA and lifecycle management. The company was founded by Todd McKinnon and J. Frederic Kerrest in 2009 and is headquartered in San Francisco, CA.

Okta Inc - Ordinary Shares - Class A

Okta Inc

Okta is rallying with cybersecurity peers as AI-related vulnerabilities and autonomous agents sharpen demand for identity and AI security, with traders pointing to the companys role in securing AI identities. Bulls see the theme supporting growth, while skeptics argue the sharp run-up is difficult to justify given Oktas modest growth and high valuation.

Blacksky Technology, Inc. is a space-based intelligence company, which engages in the business of delivering real-time imagery, analytics, and high-frequency monitoring of most critical and strategic locations, economic assets, and events. The firm is also involved in providing geospatial intelligence, imagery and related data analytic products and services, and mission systems that include the development, integration, and operation of satellite and ground systems to government and commercial customers. The company was founded in 2014 and is headquartered in Herndon, VA.

BlackSky Technology Inc - Ordinary Shares - Class A

BlackSkys expanded seven-figure Gen-3 contract with an international defense partner is drawing attention, but traders are debating why the shares remain weak despite contract wins. Some see the deals as evidence of execution, while others are focused on the steep decline and upcoming Q3 results.

American Express Co. engages in the provision of card-issuing, merchant-acquiring, and card network businesses. Its products and services include credit cards, business credit cards, corporate programs, gift cards, savings accounts and CDs, and the American Express App. It operates through the following segments: the United States Consumer Services (USCS), Commercial Services (CS), International Card Services (ICS), Global Merchant and Network Services (GMNS), and Corporate and Other. The USCS segment includes proprietary consumer cards and provides services to United States consumers. The CS segment offers corporate and small business cards and provides services to United States businesses. The ICS segment provides consumers, small businesses, and corporate cards outside the United States. The GMNS segment is involved in operating a global payments network that processes and settles card transactions, acquires merchants, and provides multi-channel marketing programs and capabilities, services and data analytics. The Corporate and Other segment covers corporate functions and certain other businesses and operations. It also operates through the following geographical segments: United States, EMEA, APAC, LACC, and Other. The EMEA segment represents Europe, the Middle East, and Africa. The APAC segment refers to Asia Pacific, Australia, and New Zealand. The LACC segment focuses on Latin America, Canada, and the Caribbean. The Other segment includes net costs which are not directly allocated to specific geographic regions. The company was founded by Henry Wells, William G. Fargo, and John Warren Butterfield on March 28, 1850 and is headquartered in New York, NY.

American Express Co.

American Express shares fell despite an earnings beat and raised profit outlook, as traders focused on plans to cut about 5% of the workforce and a slight revenue miss. Some see resilient spending and stronger guidance as positives, while others question the outlook amid restructuring and rising expenses.

Cloudflare, Inc. engages in the provision of cloud-based services to secure websites. The firm offers various products for application security, performance and reliability, network services, Zero Trust, developer platform, media delivery, insights, domain registration, and consumer services. It operates through the United States and Rest of the World geographical segments. The company was founded by Matthew Prince, Michelle Zatlyn, and Lee Holloway in July 2009 and is headquartered in San Francisco, CA.

Cloudflare Inc - Ordinary Shares - Class A

Cloudflare Inc

Cloudflare shares are drawing attention as cybersecurity stocks rally around the PHP2Shell vulnerabilities, with traders viewing Cloudflares web application firewall as a potential beneficiary because it can block exploit traffic. The move has prompted bullish momentum trading, while some traders warn against chasing the sharp gain or focus on the stocks valuation.

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Merck & Co Inc

Mercks partnership with Moderna is drawing attention after their personalized melanoma vaccine, combined with Keytruda, met Phase 3 endpoints; traders are weighing the clinical promise against results that fell short of some expectations. Discussion also questions the treatments cost and manufacturing complexity, though Mercks CEO has expressed confidence in its commercial scalability.

Palo Alto Networks, is a cybersecurity company that provides cybersecurity platforms and services to enterprises, organizations, service providers, and government entities. Its offerings include network and AI security, cloud security, security operations, and identity security solutions. The company was founded by Nir Zuk in March 2005 and is headquartered in Santa Clara, CA.

Palo Alto Networks Inc

Palo Alto Networks is rising with cybersecurity peers as AI-related vulnerabilities and escalating threat reports renew expectations for security spending; an Evercore channel survey cited by traders also points to firming enterprise budgets. The reaction is broadly bullish, though some traders question whether the sectors sharp rally is justified by already-stretched valuations.

Reddit, Inc. operates an entertainment, social networking, and news website where registered community members can submit content. The firm provides online news services where users can select and rank web content. It also offers a personalized filter on the day's story, using previous votes to determine what new things the user might like to read. The company was founded by Steven Ladd Huffman and Alexis Ohanian on June 23, 2005 and is headquartered in San Francisco, CA.

Reddit Inc. - Ordinary Shares - Class A

Reddit Inc

Reddits upcoming earnings report is the main focus, with traders watching for evidence that ad growth can offset concerns about user trends and the lack of new AI data-licensing deals. Sentiment is split between bulls citing improving ad monetization and business fundamentals, and frustrated bears pointing to the stocks weak, choppy performance and questioning whether earnings can revive it.

CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA. The firm offers a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan, and Craig Mellow on October 31, 2013 and is headquartered in Zug, Switzerland.

CRISPR Therapeutics AG

CRSP is drawing attention ahead of the CTX310 Phase 1b presentation at the AHA meeting, with traders focused on whether the in-vivo gene-editing data could validate the cardiovascular program. Reactions are mixed: some are positioning around the readout, while others are concerned about the stocks persistent range-bound trading and the CFO transition, which some view as unsettling despite reports of an orderly handoff.

Fervo Energy Co. operates as a energy company. It builds and operates power facilities in extracting geothermal energy. The company was founded by Jack Norbeck and Timothy Latimer in 2017 and is headquartered in Berkeley, CA.

Fervo Energy Co. - Ordinary Shares - Class A

Fervo Energy Co

FRVO is drawing attention amid a steep selloff and debate over a Morpheus short report questioning Fervos geothermal performance, including water recovery and project economics; investors also cite transmission constraints and potential IPO-related selling. Bears see serious execution risks, while bulls dismiss the report as biased and point to Cape Stations first power and Google contracts as evidence of progress.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Unicycive Therapeutics, Inc. (Nasdaq: $UNCY ) has a Prescription Drug User Fee Act (PDUFA) target action date of March 25, 2027 for oxylanthanum carbonate (OLC), its investigational oral phosphate binder for the treatment of hyperphosphatemia in patients with chronic kidney disease (CKD) on dialysis, now that the U.S. Food and Drug Administration (FDA) has accepted the company&#39;s New Drug Application (NDA) resubmission. The FDA has deemed the resubmission a Class II with a six-month review period from the resubmission date. 
 
Unicycive Therapeutics, Inc. is a B2i Digital Featured Company. See the company&#39;s in-depth profile at: https://b2idigital.com/unicycive-therapeutics 
 
Under the 505(b)(2) regulatory pathway, the NDA for OLC is supported by clinical, preclinical and Chemistry, Manufacturing, and Controls (CMC) data: 
 
• Three clinical studies: a Phase 1 study in healthy volunteers, a bioequivalence study in healthy volunteers, and a tolerability study of OLC in CKD patients on dialysis 
 
• Multiple preclinical studies 
 
• The resubmission includes CMC data from a new third-party drug product manufacturing vendor 
 
Regarding the review, Shalabh Gupta, M.D., Chief Executive Officer of Unicycive, stated: &quot;We hope to continue working with the FDA toward potential approval of this important medication to patients with CKD on dialysis who need additional treatment options for managing hyperphosphatemia.&quot; 
 
Read the full release: https://ir.unicycive.com/news/detail/128/unicycive-therapeutics-announces-fda-acceptance-of 
 
Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. Unicycive’s lead investigational treatment is oxylanthanum carbonate, a novel phosphate binding agent for the treatment of hyperphosphatemia in patients with chronic kidney disease who are on dialysis. Unicycive’s second investigational treatment UNI-494 is intended for the treatment of conditions related to acute kidney injury. It has been granted orphan drug designation (ODD) by the FDA for the prevention of Delayed Graft Function (DGF) in kidney transplant patients and has completed a Phase 1 dose-ranging safety study in healthy volunteers. For more information, please visit Unicycive.com and follow us on LinkedIn and X. 
 
Discover more Featured Companies, Featured Experts, and upcoming Featured Conferences at b2idigital.com. 
 
David Shapiro, Chief Executive Officer of B2i Digital, personally purchased in the open market and currently owns shares of unrestricted UNCY stock, in line with B2i Digital’s practice of investing alongside its Featured Companies. B2i Digital is not a broker-dealer or investment adviser. This post is informational and not an offer or solicitation regarding any security. See the complete Disclosure at https://b2idigital.com/disclaimer. 
 $XOMA, $RMTI, $LNTH, $XBI

David Shapiro

BioSwings™

Ev Ce

Den Tongco

fariha jabeen

Bonnie Siegmund

Linda Scott

Craig Salinas

Ariana Storck

Roberta Creech

Henry Callaghan

Michael Musto

Eugene Davenport

John Park

Melissa Vermillion

Shirley Hall

James Adair

Kelly Distaffen

Renee Blankenship

Jeanne Hodges

Micheal Fikes

Nina Studdard

Raymond Oliver

Filomena Marsh

Lucy Pena

Amber Reilly

Terry Skora

Karen Paris

Lillian Ellis

Joseph Weiler

Unicycive Therapeutics (UNCY) invents and develop medications that make a meaningful difference in the lives of kidney patients and their caregivers.

Unicycive

Unicycive | Home

b2i digital - connecting companies and investors through digital marketing, investor conferences, and direct introductions and meetings.

B2idigital

B2i Digital - Connecting companies and investors

Disclaimer - Content is provided "as is" by companies featured on the site. Conduct a trusted advisory before making investments.

Disclaimer - Consult an advisor before making any investments

Unicycive Therapeutics (NASDAQ: UNCY) is a clinical-stage biotech developing treatments for kidney disease and chronic kidney disease patients.

Unicycive Therapeutics, Inc. | Nasdaq: UNCY | B2i Digital Featured Company

Stay current with Unicycive Therapeutics press releases, business updates, and financial results announcements for UNCY investors.

Unicycive Therapeutics, Inc.

Unicycive Therapeutics Announces FDA Acceptance of Oxylanthanum Carbonate New Drug Application Resubmission and PDUFA Date of March 25, 2027

StockTwits Web

Unicycive Therapeutics Inc

XOMA Corp

Rockwell Medical Inc

Lantheus Holdings Inc

SPDR S&P Biotech ETF

 ) has a Prescription Drug User Fee Act (PDUFA) target action date of March 25, 2027 for oxylanthanum carbonate (OLC), its investigational oral phosphate binder for the treatment of hyperphosphatemia in patients with chronic kidney disease (CKD) on dialysis, now that the U.S. Food and Drug Administration (FDA) has accepted the company's New Drug Application (NDA) resubmission. The FDA has deemed the resubmission a Class II with a six-month review period from the resubmission date. 
 
Unicycive Therapeutics, Inc. is a B2i Digital Featured Company. See the company's in-depth profile at: https://

/unicycive-therapeutics 
 
Under the 505(b)(2) regulatory pathway, the NDA for OLC is supported by clinical, preclinical and Chemistry, Manufacturing, and Controls (CMC) data: 
 
• Three clinical studies: a Phase 1 study in healthy volunteers, a bioequivalence study in healthy volunteers, and a tolerability study of OLC in CKD patients on dialysis 
 
• Multiple preclinical studies 
 
• The resubmission includes CMC data from a new third-party drug product manufacturing vendor 
 
Regarding the review, Shalabh Gupta, M.D., Chief Executive Officer of Unicycive, stated: "We hope to continue working with the FDA toward potential approval of this important medication to patients with CKD on dialysis who need additional treatment options for managing hyperphosphatemia." 
 
Read the full release: https://ir.

/news/detail/128/unicycive-therapeutics-announces-fda-acceptance-of 
 
Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. Unicycive’s lead investigational treatment is oxylanthanum carbonate, a novel phosphate binding agent for the treatment of hyperphosphatemia in patients with chronic kidney disease who are on dialysis. Unicycive’s second investigational treatment UNI-494 is intended for the treatment of conditions related to acute kidney injury. It has been granted orphan drug designation (ODD) by the FDA for the prevention of Delayed Graft Function (DGF) in kidney transplant patients and has completed a Phase 1 dose-ranging safety study in healthy volunteers. For more information, please visit 

 and follow us on LinkedIn and X. 
 
Discover more Featured Companies, Featured Experts, and upcoming Featured Conferences at 

. 
 
David Shapiro, Chief Executive Officer of B2i Digital, personally purchased in the open market and currently owns shares of unrestricted UNCY stock, in line with B2i Digital’s practice of investing alongside its Featured Companies. B2i Digital is not a broker-dealer or investment adviser. This post is informational and not an offer or solicitation regarding any security. See the complete Disclosure at https://

Unicycive Therapeutics, Inc. has reached an important regulatory milestone with FDA acceptance of its OLC NDA resubmission and a PDUFA target action date of March 25, 2027. OLC is being developed to address hyperphosphatemia in dialysis patients with chronic kidney disease.  
Learn more about this B2i Digital Featured Company profile at: https://b2idigital.com/unicycive-therapeutics

Unicycive Therapeutics, Inc. has reached an important regulatory milestone with FDA acceptance of its OLC NDA resubmission and a PDUFA target action date of March 25, 2027. OLC is being developed to address hyperphosphatemia in dialysis patients with chronic kidney disease.  
Learn more about this B2i Digital Featured Company profile at: 